C 2 pill
Searched over 200M research papers
Summary
2 papers analyzed
These studies suggest that a higher number of hepatitis C pills can lead to poorer adherence to treatment, and that Vitamin C can reduce the need for opioids in managing acute musculoskeletal pain in emergency department patients.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Impact of Pill Burden on Hepatitis C Medication Adherence
Introduction to Hepatitis C Pill Burden
Hepatitis C virus (HCV) treatment has evolved significantly with the advent of direct-acting antivirals (DAAs). However, the pill burden associated with these treatments remains a critical factor influencing patient adherence. Pill burden refers to the number of pills a patient must take daily, which can impact their ability to consistently follow their prescribed regimen.
Pill Burden Before and After HCV Treatment Initiation
A study examining the pill burden among patients newly treated for HCV infection found that the mean overall pill burden increased significantly after the initiation of DAA treatment. Before starting HCV treatment, patients had an average pill burden of 5.4 pills per day, which rose to 7.7 pills per day post-initiation (p < .001). This increase highlights the substantial medication load that patients must manage during their treatment.
Association Between Pill Burden and Medication Adherence
The study further explored the relationship between HCV pill burden and gaps in therapy. It was observed that higher pill burdens were associated with lower adherence to medication. Specifically, patients taking 2 HCV pills per day had an adjusted odds ratio (OR) of 1.75 for experiencing a gap of 15 days or more in their therapy, compared to those taking just 1 pill per day. This risk increased to an OR of 2.11 for patients taking 3 or more pills per day. These findings underscore the importance of considering pill burden when selecting HCV treatments to enhance adherence and treatment outcomes.
Conclusion
In conclusion, the pill burden associated with HCV treatment is a significant factor that can affect patient adherence. As the number of pills increases, so does the likelihood of gaps in therapy, which can compromise treatment efficacy. Therefore, minimizing pill burden should be a key consideration in the management of HCV to improve adherence and overall treatment success.
Sources and full results
Most relevant research papers on this topic
